Biotech
Vedanta Biosciences
Vedanta Biosciences raises $108M Series D at $550M valuation
$108M
Total Raised
Series D
Latest Round
2010
Founded
150+
Employees
501 Boylston Street, Boston, MA 02116
1 min read
Quick Facts
Valuation
$550M
Latest Round Size
$108M
Latest Round Date
October 2024
Vedanta Biosciences: Series D Funding Round
Vedanta Biosciences has successfully raised $108M in Series D funding, reaching a valuation of $550M.
Company Overview
Microbiome-derived therapeutics
Funding Details
The Series D round was led by Johnson & Johnson Innovation, with participation from Mitsui & Co, Puretech Health, Flagship Pioneering.
Company Information
- Headquarters: 501 Boylston Street, Boston, MA 02116
- Founded: 2010
- Employees: 150+
- Category: Biotech
Investment
Vedanta Biosciences plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Johnson & Johnson Innovation: Verified investor in Series D
- Mitsui & Co: Verified investor in Series D
- Puretech Health: Verified investor in Series D
- Flagship Pioneering: Verified investor in Series D
Key Investors
Johnson & Johnson Innovation
Lead Investor
Verified investor in Series D
Mitsui & Co
Investor
Verified investor in Series D
Puretech Health
Investor
Verified investor in Series D
Flagship Pioneering
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M